ACAD logo

ACAD
Acadia Pharmaceuticals Inc

13,075
Mkt Cap
$3.78B
Volume
1.3M
52W High
$28.35
52W Low
$13.40
PE Ratio
9.70
ACAD Fundamentals
Price
$22.32
Prev Close
$22.20
Open
$21.99
50D MA
$23.13
Beta
0.97
Avg. Volume
1.99M
EPS (Annual)
$2.30
P/B
3.08
Rev/Employee
$1.34M
$3,771.04
Loading...
Loading...
News
all
press releases
ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC raised its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 25.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 658,813 shares...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fou...
MarketBeat·10d ago
News Placeholder
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·10d ago
News Placeholder
ACADIA Pharmaceuticals (NASDAQ:ACAD) Raised to "Buy" at Bank of America
Bank of America raised ACADIA Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $29.00 target price on the stock in a report on Wednesday...
MarketBeat·12d ago
News Placeholder
Hudson Bay Capital Management LP Sells 119,700 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Hudson Bay Capital Management LP cut its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 63.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 70,300 shares of the biopharmaceutical company's st...
MarketBeat·15d ago
News Placeholder
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug Oct, ACP-211 Next Year
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives discussed upcoming clinical readouts and pipeline priorities during the company's virtual CNS conference, with a focus on remlifanserin (formerly...
MarketBeat·20d ago
News Placeholder
Algert Global LLC Has $8.54 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD
Algert Global LLC raised its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 653.6% during the third quarter, according to its most recent disclosure with the Securities and...
MarketBeat·21d ago
News Placeholder
Fred Alger Management LLC Sells 820,421 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Fred Alger Management LLC lowered its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 34.4% during the third quarter, according to the company in its most recent Form...
MarketBeat·22d ago
News Placeholder
Braidwell LP Makes New $50.76 Million Investment in ACADIA Pharmaceuticals Inc. $ACAD
Braidwell LP bought a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The firm bought 2,378,655...
MarketBeat·23d ago
News Placeholder
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
Zacks·24d ago
<
1
2
...
>

Latest ACAD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.